Hers vs Medvi

Choose hers if: You are female with multiple health needs beyond weight loss—particularly common combinations like obesity + PCOS-related hair loss, obesity + depression/anxiety, or obesity + hormonal skin issues benefiting from coordinated women-specific medical care. You value complete women's health platform consolidating diverse treatments (weight loss, hair loss, mental health, skincare) through integrated provider network with specialized female health expertise. You prioritize established operational reliability (7+ years proven service) providing confidence in treatment continuity for chronic management. You may utilize tirzepatide for superior weight loss efficacy versus semaglutide-only restriction. You appreciate multi-category platform maturity, sophisticated infrastructure, and proven business viability despite higher costs ($199-349/month).

Choose Medvi if: You need exclusively weight loss medication at absolute lowest cost without other health services, with $197-247/month providing meaningful savings of $288-1,224 annually compared to hers. You have straightforward medical history unlikely to benefit from complete women's health expertise or multi-condition coordination. You can accept emerging platform (<2 years operational history) without extensive validation of long-term reliability or business sustainability. You are satisfied with semaglutide-only access without need for tirzepatide option. You serve any gender (men, women, non-binary) as Medvi provides universal access versus hers female-only policy. You prioritize immediate cost minimization over platform maturity, multi-service integration, and operational certainty.

Bottom line: hers and Medvi serve different patient needs—hers offers complete women's health integration ($199-349/month) with 7+ years proven reliability, multi-category coordination (weight loss + hair loss + mental health + skincare), specialized female health expertise, dual GLP-1 formulary, and established infrastructure serving female patients with multiple interconnected health concerns, while Medvi provides ultra-budget single-category weight loss ($197-247/month) with universal gender access, emerging platform status (<2 years), semaglutide-only restriction, and minimal services beyond medication for cost-conscious patients of any gender seeking exclusively lowest-price GLP-1 access. For women with multiple health needs, PCOS, depression, or other conditions benefiting from coordinated women-specific care, hers integrated platform delivers superior value through complete expertise, proven reliability, treatment coordination, and medication options despite higher costs. For patients seeking exclusively budget-focused weight loss without gender-specialized services or multi-condition needs, Medvi's meaningful savings ($288-1,224 annually) may justify trade-offs in platform maturity, service scope, and operational certainty—though emerging platform status presents greater long-term reliability uncertainty compared to hers established 7+ year track record.